ONCODES.PREC.MED. EO-34 (ZR8) — Tangible Net Worth Ratio
ONCODES.PREC.MED. EO-34 (ZR8) has a Tangible Net Worth Ratio of 68.9% as of December 2023. This metric is calculated by deducting intangible assets (€1.15 Million) from net assets (€3.69 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See ONCODES.PREC.MED. EO-34 net assets for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ONCODES.PREC.MED. EO-34 Tangible Net Worth Ratio (2021–2023)
This chart shows how ONCODES.PREC.MED. EO-34's Tangible Net Worth Ratio has changed across 3 annual periods from 2021 to 2023. As of December 2023, the ratio stands at 68.9%, reflecting net assets of €3.69 Million with intangible assets of €1.15 Million EUR. Also explore ONCODES.PREC.MED. EO-34 (ZR8) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for ONCODES.PREC.MED. EO-34 (2021–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2023, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see ONCODES.PREC.MED. EO-34 market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 68.9% | €3.69 Million | €1.15 Million | €16.63 Million | ▼ -24.3 pp |
| 2022 | 93.3% | €11.78 Million | €794.47K | €18.37 Million | ▲ +8.0 pp |
| 2021 | 85.3% | €4.20 Million | €619.37K | €8.37 Million | — |